CN107567450B - 用作tnf抑制剂的杂环化合物 - Google Patents

用作tnf抑制剂的杂环化合物 Download PDF

Info

Publication number
CN107567450B
CN107567450B CN201680026732.5A CN201680026732A CN107567450B CN 107567450 B CN107567450 B CN 107567450B CN 201680026732 A CN201680026732 A CN 201680026732A CN 107567450 B CN107567450 B CN 107567450B
Authority
CN
China
Prior art keywords
tetrahydroimidazo
dipyridine
phenyl
methoxypyridin
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680026732.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN107567450A (zh
Inventor
L·R·马尔桑
S·T·弗罗布莱斯基
T·G·M·达尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN107567450A publication Critical patent/CN107567450A/zh
Application granted granted Critical
Publication of CN107567450B publication Critical patent/CN107567450B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201680026732.5A 2015-03-18 2016-03-17 用作tnf抑制剂的杂环化合物 Active CN107567450B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562134800P 2015-03-18 2015-03-18
US62/134,800 2015-03-18
PCT/US2016/022742 WO2016149439A1 (en) 2015-03-18 2016-03-17 Heterocyclic compounds useful as inhibitors of tnf

Publications (2)

Publication Number Publication Date
CN107567450A CN107567450A (zh) 2018-01-09
CN107567450B true CN107567450B (zh) 2020-03-13

Family

ID=55640934

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680026732.5A Active CN107567450B (zh) 2015-03-18 2016-03-17 用作tnf抑制剂的杂环化合物

Country Status (14)

Country Link
US (1) US10112944B2 (enExample)
EP (1) EP3271362B1 (enExample)
JP (1) JP6779899B2 (enExample)
KR (1) KR102696304B1 (enExample)
CN (1) CN107567450B (enExample)
AU (1) AU2016233202A1 (enExample)
BR (1) BR112017019605A2 (enExample)
CA (1) CA2980161A1 (enExample)
EA (1) EA201792054A1 (enExample)
ES (1) ES2803650T3 (enExample)
IL (1) IL254430A0 (enExample)
MX (1) MX2017011577A (enExample)
SG (1) SG11201707473VA (enExample)
WO (1) WO2016149439A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2797685T3 (es) 2015-03-18 2020-12-03 Bristol Myers Squibb Co Compuestos heterocíclicos tricíclicos útiles como inhibidores de TNF
EA032315B1 (ru) 2015-03-18 2019-05-31 Бристол-Маерс Сквибб Компани Замещенные трициклические гетероциклические соединения
AR104293A1 (es) 2015-04-17 2017-07-12 Abbvie Inc Indazolonas como moduladores de la señalización de tnf
US9856253B2 (en) 2015-04-17 2018-01-02 Abbvie, Inc. Tricyclic modulators of TNF signaling
US20160304496A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
CN108137609B (zh) 2015-08-03 2021-07-16 百时美施贵宝公司 用作TNFα的调节剂的环状化合物
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013186229A1 (en) * 2012-06-11 2013-12-19 Ucb Pharma S.A. Tnf -alpha modulating benzimidazoles
WO2014009295A1 (en) * 2012-07-13 2014-01-16 Ucb Pharma S.A. Imidazopyridine derivatives as modulators of tnf activity

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391806A (en) * 1982-07-12 1983-07-05 The Dow Chemical Company Substituted tetrahydropyridazino-(1,6-A)benzimidazoles and use as bronchodilators
AU741772B2 (en) 1997-02-25 2001-12-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase
JPWO2003064422A1 (ja) 2002-01-31 2005-05-26 第一製薬株式会社 イミダゾ［１，２−ａ］ピリジン誘導体
AU2003298839A1 (en) 2002-12-03 2004-06-23 Isis Pharmaceuticals, Inc. Benzimidazoles and analogs thereof as antivirals
US20050124638A1 (en) 2003-12-08 2005-06-09 Swayze Eric E. Benzimidazoles and analogs thereof as antivirals
WO2008072682A1 (ja) * 2006-12-15 2008-06-19 Daiichi Sankyo Company, Limited イミダゾ［１，２－ｂ］ピリダジン誘導体
WO2009045174A1 (en) 2007-10-05 2009-04-09 S*Bio Pte Ltd 2-morpholinylpurines as inhibitors of pi3k
JP2009227599A (ja) 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
CN101717397B (zh) 2008-10-09 2012-11-28 中国科学院上海药物研究所 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
WO2012148550A1 (en) 2011-02-25 2012-11-01 Myrexis, Inc. Prodrugs of therapeutic compounds
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
BR112015009649A2 (pt) * 2012-11-07 2017-07-04 Hoffmann La Roche composto de triazolo
WO2014080241A1 (en) * 2012-11-21 2014-05-30 Piramal Enterprises Limited Imidazopyridine compounds and uses thereof
WO2015008611A1 (ja) 2013-07-18 2015-01-22 株式会社 村田製作所 積層型インダクタ素子の製造方法
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321743D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321742D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321744D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321735D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
BR112016013018A2 (pt) 2013-12-09 2017-08-08 Ucb Biopharma Sprl Derivados heteroaromáticos bicíclicos fundidos como moduladores de atividade de tnf
GB201321739D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
RU2695664C1 (ru) 2013-12-09 2019-07-25 Юсб Байофарма Спрл Производные имидазопиридина в качестве модуляторов активности tnf
CN113248506A (zh) 2014-10-06 2021-08-13 西格诺药品有限公司 取代的氨基嘌呤化合物、其组合物及其治疗方法
ES2797685T3 (es) 2015-03-18 2020-12-03 Bristol Myers Squibb Co Compuestos heterocíclicos tricíclicos útiles como inhibidores de TNF
EA032315B1 (ru) 2015-03-18 2019-05-31 Бристол-Маерс Сквибб Компани Замещенные трициклические гетероциклические соединения

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013186229A1 (en) * 2012-06-11 2013-12-19 Ucb Pharma S.A. Tnf -alpha modulating benzimidazoles
WO2014009295A1 (en) * 2012-07-13 2014-01-16 Ucb Pharma S.A. Imidazopyridine derivatives as modulators of tnf activity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"A Flexible Three-Component Synthesis of Novel d-Amino Acids Incorporating an Imidazo[1,2-a]pyridine Backbone";Ivana Veljkovic et al;《SYNTHESIS》;20060719(第16期);第2677-2684页 *
"Synthesis of C8-C9 Annulated Purines by Iron-Catalyzed C-H Amination";Jens Maes et al.;《Chem. Eur. J.》;20130603;第19卷;第9137-9141页 *
1629516-25-1;美国化学会;《美国化学会》;20141021;第1页 *
Vikas Chaudhary et al.."Scaffold-hopping and hybridization based design and building block strategic synthesis of pyridine-annulated purines: discovery of novel apoptotic anticancer agents".《RSC Advances》.2015,第5卷第26051–26060页. *

Also Published As

Publication number Publication date
US20180072728A1 (en) 2018-03-15
BR112017019605A2 (pt) 2018-05-08
IL254430A0 (en) 2017-11-30
EP3271362A1 (en) 2018-01-24
KR102696304B1 (ko) 2024-08-16
ES2803650T3 (es) 2021-01-28
EA201792054A1 (ru) 2018-01-31
SG11201707473VA (en) 2017-10-30
CN107567450A (zh) 2018-01-09
JP2018512062A (ja) 2018-05-10
AU2016233202A1 (en) 2017-11-09
CA2980161A1 (en) 2016-09-22
JP6779899B2 (ja) 2020-11-04
US10112944B2 (en) 2018-10-30
WO2016149439A1 (en) 2016-09-22
KR20170129192A (ko) 2017-11-24
EP3271362B1 (en) 2020-04-22
MX2017011577A (es) 2017-10-26

Similar Documents

Publication Publication Date Title
CN107567450B (zh) 用作tnf抑制剂的杂环化合物
CN112752756B (zh) 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
CN108473500B (zh) 用作IL-12、IL-23和/或IFNα响应的调节剂的咪唑并哒嗪化合物
CN116102535A (zh) 一种含氮化合物、其制备方法及应用
CN107074804B (zh) 咔唑衍生物
CN114728962A (zh) 血浆激肽释放酶抑制剂及其用途
CN111936486A (zh) 用作IL-12、IL-23和/或IFNα响应的调节剂的包含吡啶的杂环化合物
CN107635992B (zh) 用作tnf抑制剂的三环杂环化合物
CN107108555B (zh) 三环阻转异构体化合物
CN108137547A (zh) 可用作TNFα调节剂的杂环化合物
CN108137609B (zh) 用作TNFα的调节剂的环状化合物
CN114829350B (zh) 经取代的咔唑化合物
WO2023046149A1 (zh) 喹喔啉类化合物及其医药用途
JP2023539136A (ja) Ｔｌｒ９阻害剤として有用な置換ヘテロアリール化合物
CN112955450A (zh) 经取代的吲哚和吲唑化合物
CN117355523A (zh) 血浆激肽释放酶的多环抑制剂
WO2021093817A1 (zh) 免疫调节化合物、组合物及其应用
CN116096717A (zh) 咪唑并[1,2-a]吡啶和[1,2,4]三唑并[1,5-a]吡啶衍生物作为TLR9抑制剂用于纤维化的治疗
CN114845777A (zh) 四氢苯并-喹啉磺酰胺衍生物化合物
WO2023246837A1 (zh) 一类具有嘧啶并六元环结构的化合物、包含其的药物组合物及其应用
JP7573596B2 (ja) Ｉｒａｋ４阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物
CN116236583A (zh) 一种含Bcl-2/Bcl-xl抑制剂的组合物及其制备方法与应用
WO2025237389A1 (zh) 三环wrn抑制剂、其制备方法及其应用
WO2023236947A1 (zh) 取代的哒嗪-3-甲酰胺化合物作为tyk2抑制剂
CN120152957A (zh) 用作tlr9抑制剂的经取代的喹诺酮

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant